An FDA advisory panel concluded that the benefits of Johnson & Johnson's experimental rheumatoid arthritis drug, sirukumab, do not outweigh the risks.
The panel voted 12-1 against the approval of the drug, citing safety concerns.
Two days prior, a FDA report concluded that more deaths were reported in patients taking sirukumab than those taking a placebo.
Currently, there are two drugs in the same class already on the market -- Roche Holding's Actemra, and Sanofi and Regeneron Pharmaceuticals’ Kevzara.
Read the Reuters release